Cariprazine also demonstrated statistically significant superiority over placebo on YMRS response ( 50 % improvement : cariprazine , 58.9 % ; placebo , 44.1 % ; P = 0.0097 ) and remission ( YMRS total score12 : cariprazine , 51.9 % ; placebo , 34.9 % ; P = 0.0025 ) and mean change in CGI-S ( P = 0.0027 ) score and Positive and Negative Syndrome Scale ( PANSS ) ( P = 0.0035 ) total score .